We scan new podcasts and send you the top 5 insights daily.
Clinicians are abandoning watchful waiting in favor of proactive mitigation to avoid fatal pulmonary complications from mirvetuximab. Even asymptomatic patients showing rapid radiographic ground-glass changes can safely receive short, quick steroid tapers rather than the prolonged multi-month regimens used for checkpoint inhibitors.
While caution is necessary, a patient's prior history of pneumonitis does not automatically disqualify them from receiving an ADC with a known risk of this side effect. Clinical judgment is key; if the prior event was from a specific, known drug combination and has fully resolved, proceeding with careful monitoring can be a viable option.
The discovery of low-grade, asymptomatic interstitial lung disease (ILD) on scans for patients on certain ADCs does not mandate permanent discontinuation. By holding the drug, initiating steroids, and involving pulmonology, the inflammation can resolve, often allowing the patient to safely resume a highly effective therapy.
With ADCs carrying a risk of interstitial lung disease (ILD), a critical safety measure is to act on radiological findings alone. Even if a patient is completely asymptomatic, new ground-glass opacities on a CT scan require an immediate treatment hold to prevent potentially rapid and severe pneumonitis.
To manage the risk of interstitial lung disease (ILD) with TDXD, experts now recommend routine screening with high-resolution chest CT scans every 6-12 weeks. This practice aims to catch asymptomatic, grade 1 ILD early, allowing for treatment holds and steroid intervention, which may preserve the option to rechallenge.
Unlike pneumonitis from immune checkpoint inhibitors, which responds quickly to steroids, pneumonitis from ADCs like trastuzumab deruxtecan is less responsive and slower to resolve. This critical difference requires a lower threshold for holding therapy and more cautious management to avoid permanent lung damage.
The management of treatment-induced pneumonitis differs significantly between drug classes. While clinicians may treat through low-grade pneumonitis from immune checkpoint inhibitors, the safest approach for antibody-drug conjugates (ADCs) like TDXD is to stop the drug immediately upon any radiographic evidence, even if the patient is asymptomatic.
Suspected interstitial lung disease on chest imaging can closely resemble infectious conditions like pneumonia. Involving pulmonary specialists early for inpatient evaluation, viral testing, or bronchoscopy prevents physicians from unnecessarily stopping effective trastuzumab deruxtecan therapy for a misdiagnosed toxicity, while ensuring true pulmonary complications receive rapid steroid or antibiotic intervention.
Unlike some immunotherapy guidelines, experts recommend immediate steroid treatment for even Grade 1 (asymptomatic) ADC-induced pneumonitis or interstitial lung disease (ILD) found on scans. This aggressive, proactive approach is considered necessary due to the risk of rapid clinical deterioration, prioritizing safety and the ability to resume cancer therapy.
Abruptly stopping JAK inhibitors can trigger a potentially fatal SIRS-like syndrome from a cytokine storm. Clinicians must taper the dose. If an abrupt stop is necessary (e.g., for a procedure), bridging the patient with prednisone is a critical and effective strategy to prevent this severe withdrawal reaction.
For transplant or autoimmune patients, a prophylactic, tapering steroid regimen (e.g., 40mg prednisone tapered to 10mg) around immunotherapy infusions can prevent organ rejection or disease flares. This "conditioning" allows for safer administration of life-saving immunotherapy in vulnerable populations.